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1. Introduction
1.1. Type 1 diabetes mellitus
Diabetes mellitus is considered to be one of the most common chronic diseases worldwide,
and recognized as one of the leading causes of morbidity and mortality (American Diabetes
Association, 2010). It has been reported that the prevalence of diabetes mellitus will increase
from 6% to over 10% in the next decade (Rosen et al., 2001). According to the World Health
Organization in 2000, a total of 171 million people in all age groups worldwide (2.8% of the
global population) have been affected by diabetes mellitus, and the number of persons is ex‐
pected to increase to 366 million (4.4% of the global population) by 2030 (Wild et al., 2004).
Type 1 diabetes mellitus accounts for 5-10% of all diagnosed cases of diabetes mellitus, and
exhibits hyperglycemia as its hallmark. It is caused by pancreatic β-islet cell failure with re‐
sulting insulin deficiency mortality and risk factors may be autoimmune, genetic, or envi‐
ronmental (American Diabetes Association, 2004). Type 1 diabetes mellitus is an
autoimmune disorder involving immune-mediated recognition of islet β-cells by auto-reac‐
tive T cells. This subsequently leads to the liberation of pro-inflammatory cytokines and re‐
active oxygen species. There is destruction of pancreatic β-cells in the islets of Langerhans
and loss of insulin secretion (Delmastro & Piganelli, 2011). The Jun kinase pathway is also
activated by the pro-inflammatory cytokines, and there is evidence that oxidative stress is
involved in β-cell destruction (Kaneto et al., 2007). The loss of β-cell mass consequential to
the activation of pro-apoptotic signaling events is increasingly recognized as a causal and
committed stage in the development of type 1 diabetes mellitus (Watson & Loweth, 2009).
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Moreover, pancreatic β-cells are sensitive to cytotoxic damage caused by reactive oxygen
species as gene expression and activity of antioxidant enzymes such as glutathione peroxi‐
dase activity is decreased in these cells (Lenzen et al., 1996).
Increasing evidence in both experimental and clinical studies suggests that oxidative stress
plays a central role in the onset of diabetes mellitus as well as in the development of vascu‐
lar and neurologic complications of the disease (Niedowicz & Daleke, 2005). Studies advanc‐
ing the role of oxidative stress in vascular endothelial cells proposed that oxidative stress
mediate the diversion of glycolytic intermediates into pathological pathways (Rolo & Pal‐
meira, 2006; Turk, 2010). Oxidative stress is increased in diabetes mellitus owing to an in‐
crease in the production of oxygen free radicals and a deficiency in antioxidant defense
mechanisms. Free radicals are formed disproportionately in diabetes by glucose oxidation,
non-enzymatic glycation of proteins, and the subsequent oxidative degradation of glycated
proteins (Rodiño-Janeiro et al., 2010). Abnormally high levels of free radicals and the simul‐
taneous decline of antioxidant defense mechanisms can lead to damage of cellular organ‐
elles and enzymes, increased lipid peroxidation, and development of insulin resistance
(Ceriello, 2006).
This review will explore recent evidence in the literature of the use of biomarkers to assess
oxidative stress which is recognized as a significant mediator in the development of macro‐
vascular or cardiovascular complication in type 1 diabetes mellitus, as well as the potential
for prevention of complications through the use of antioxidants. There is also a search for
other biomarker of oxidative stress which might be clinically useful in patients with diabetes
mellitus. Such a biomarker could potentially indicate the severity of disease, identify those
at increased risk of complications and monitor response to treatment.
2. Oxidative stress and beta-cell destruction
Impairment in the oxidant/antioxidant equilibrium creates a condition known as oxidative
stress. There is a complex interaction between antioxidants and oxidants such as reactive
oxygen species, which modulates the generation of oxidative stress. Oxidative stress takes
place in a cellular system when the generation of reactive oxygen species increases and over‐
whelms the body’s antioxidant capacity and defenses (Baynes, 1991). If the free radicals are
not removed by the cellular antioxidants, they may attack and damage lipids, carbohy‐
drates, proteins and nucleic acids (Baynes & Thorpe, 1999).
Oxidative stress is known to be a component of molecular and cellular tissue damage mecha‐
nisms in a wide spectrum of human diseases (Maritim et al., 2003; Isabella et al., 2006). There is
growing evidence that have connected oxidative stress to a variety of pathological conditions,
including cancer, cardiovascular diseases, chronic inflammatory disease, post-ischaemic or‐
gan injury, diabetes mellitus, xenobiotic/drug toxicity, and rheumatoid arthritis (El Farama‐
wy & Rizk, 2011; Samanthi et al., 2011). In recent years, much attention has been focused on
the role of oxidative stress. It has been reported that oxidative stress participates in the pro‐
gression and pathogenesis of secondary diabetic complications. This includes impairment of
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insulin action and elevation of the complication incidence (Ceriello, 2006). Furthermore, there
is evidence for the role of reactive oxygen species and oxidative stress in the development of
type 1 diabetic complications including retinopathy, nephropathy, neuropathy, and accelerat‐
ed coronary artery disease (Phillips et al., 2004; Niedowicz & Daleke, 2005).
It has also been reported that oxidative stress induced by reactive oxygen and nitrogen spe‐
cies is critically involved in the impairment of β-cell function, and thus play a role in the
pathology of type 1 diabetes mellitus (West, 2000). Islet β-cells are highly susceptible to oxi‐
dative stress because of their reduced levels of endogenous antioxidants (Azevedo-Martins et
al., 2003; Kajikawa et al., 2002). With decreased antioxidant capacity, β-cells are extremely
sensitive towards oxidative stress. Cell metabolism and potassium (adenosine-5’-triphos‐
phate) channels in β-cells are important targets for reactive oxygen species and other oxi‐
dants. The alterations of potassium (adenosine-5’-triphosphate) channel activity by the
oxidants, is crucial for oxidant-induced dysfunction as genetic ablation of potassium (adeno‐
sine-5’-triphosphate) channels attenuates the effects of oxidative stress on β-cell function
(Drews, 2010).
Oxidative stress may reduce insulin sensitivity and damage the β-cells within the pancreas.
The reactive oxygen species produced by oxidative stress can penetrate through cell mem‐
branes and cause damage to the β-cells of pancreas (Chen et al., 2005; Lepore et al., 2004).
Reactive oxygen species produced from free fatty acids can cause mitochondrial deoxyribo‐
nucleic acid damage and impaired pancreatic β-cell function (Rachek et al., 2006). Mitochon‐
drial and nitrogen oxides (NOx)-derived reactive oxygen species have been implicated in β-
cell destruction and subsequently type 1 diabetes mellitus. Furthermore, increased glucose
can cause rapid induction of the Krebs cycle within the β-cell mitochondria, leading to aug‐
mented reactive oxygen species production (Newsholme et al., 2007). The superoxide leaked
from the mitochondria can contribute to the formation of hydrogen peroxide which may
play a role in uncoupling glucose metabolism from insulin secretion (Maechler et al., 1999).
3. Oxidative stress induced by hyperglycaemia in type 1diabetes
3.1. Pathways involved in the production of oxidants
There are multiple sources of reactive oxygen species production in diabetes including those
of non-mitochondrial and mitochondrial origins. Reactive oxygen species accelerates four
important molecular mechanisms that are involved in oxidative tissue damage induced by
hyperglycemia. These four pathways are increased advanced glycation end product, in‐
creased hexosamine pathway flux, activation of protein kinase C, and increased polyol path‐
way flux (also known as the sorbitol-aldose reductase pathway) (Rolo & Palmeira, 2006).
In the polyol pathway, the two enzymes aldose reductase and sorbitol dehydrogenase cause
reactive oxygen species production. Glucose is reduced to sorbitol through the use of re‐
duced nicotinamide adenine dinucleotide phosphate, a reaction catalyzed by aldose reduc‐
tase. This pathway metabolizes 30 - 35% of the glucose present during hyperglycemia. The
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available reduced nicotinamide adenine dinucleotide phosphate is depleted resulting in the
reduction of glutathione regeneration and nitric oxide synthase activity (Ramana et al.,
2003). The oxidation of sorbitol to fructose with the concomitant production of reduced nico‐
tinamide adenine dinucleotide is catalyzed by sorbitol dehydrogenase. The reduced nicoti‐
namide adenine dinucleotide phosphate may be used by nicotinamide adenine dinucleotide
phosphate oxidases to generate superoxide anion (Moore & Roberts, 1998). Vitamin C sup‐
plementation has been found to be effective in reducing sorbitol accumulation in the red
blood cells of diabetic patients. In a study conducted by Cunningham et al. (1994) who in‐
vestigated the effect of two different doses of vitamin C supplements (100 and 600 mg) dur‐
ing a 58 day trial on young adults with type 1 diabetes mellitus, vitamin C supplementation
at either dose within 30 days normalized sorbitol levels.
Glucose at high concentrations undergoes non-enzymatic reactions with primary amino
groups of proteins to form glycated residues called Amadori products. These early glycation
products undergo further complex reactions, such as rearrangement, dehydration, and con‐
densation, to become irreversibly cross-linked, heterogeneous fluorescent derivatives called
advanced glycation end products (Thornalley, 2002). The advanced glycation end products
binds to a cell surface receptor known as receptor for advanced glycation end product. As a
result of interaction of advanced glycation end products, with receptor for advanced end
product, there is the induction of the synthesis of reactive oxygen species via a mechanism
which involves localization of pro-oxidant molecules at the cell surface (Yan et al., 1994) and
the participation of activated nicotinamide adenine dinucleotide phosphate oxidase (Wauti‐
er et a., 2001). The reactive aldehydes methylglyoxal and glyoxal are produced from enzy‐
matic and non-enzymatic degradation of glucose, lipid and protein catabolism, and lipid
peroxidation. These aldehydes form advanced glycation end products with proteins that are
implicated in diabetic complications. Han et al. (2007) assessed plasma methylglyoxal and
glyoxal using a novel liquid chromatography-mass spectrophotometry method in 56 young
patients (6 - 22 years) with type 1 diabetes mellitus without complications. They found that
mean plasma methylglyoxal and glyoxal levels were higher in the diabetic patients com‐
pared with their non-diabetic counterparts. They suggest that increased plasma methyl‐
glyoxal and glyoxal levels give an indication of future diabetic complications and
emphasized the need for aggressive management (Han et al., 2007).
It has been shown that through receptor for advanced glycation end products mediated ef‐
fects, advanced glycation end product induces reactive oxygen species production possibly
through an nicotinamide adenine dinucleotide phosphate oxidase, and the subsequent ex‐
pression of inflammatory mediators and activation of redox-sensitive transcription factors
(Wautier et al., 2001; Schmidt et al., 1996). Furthermore, advanced glycation end products,
binding to receptor for advanced glycation end product activate protein kinase C-α-mediat‐
ed activation of nuclear factor-κB (NFκβ) and nicotinamide adenine dinucleotide phosphate
oxidase. This may cause the generation of mitochondrial reactive oxygen species and induce
the production of various inflammatory cytokines further aggravating oxidative stress
(Simm et al., 1997).
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Advanced glycation end product in high concentration in body is toxic and can modify the
structure of intracellular proteins especially those involved in gene transcription, and can
cause damage to biological membranes and the endothelium. It may diffuse to the extracel‐
lular space and directly modify extracellular proteins such as laminin and fibronectin to dis‐
turb signaling between the matrix and cells that act via receptor for advanced glycation end
products, which is present on many vascular cells (Bierhaus et al. 1998). In addition, ad‐
vanced glycation end products can modify blood proteins such as albumin, causing them to
bind to advanced glycation end product receptors on macrophages/mesangial cells and in‐
crease the production of growth factors and proinflammatory cytokines (Brownlee, 2005).
Kostolanská et al. (2009) observed significantly higher glycated hemoglobin, serum ad‐
vanced glycation end products and advanced oxidation protein products concentrations in
81 patients with type 1 diabetes mellitus compared with controls. They suggest that the
measurement of glycated hemoglobin, serum advanced glycation end products and ad‐
vanced oxidation protein products may be useful to predict the risk of development of dia‐
betic complications (Kostolanská et al., 2009).
Antioxidants or antibodies against receptor for advanced glycation end product prevent
both oxidative stress and the downstream signaling pathways that can be activated by liga‐
tion of receptor for advanced glycation end product. Advanced glycation end product-medi‐
ated reaction oxygen species production is implicated in diabetic vascular complications and
in blood vessel endothelial activation (Cameron & Cotter, 1999; Mullarkey et al., 1990). The
formation and accumulation of advanced glycation end products have been involved in the
development and progression of diabetic micro- and macroangiopathy. The advanced glyca‐
tion end product-receptor for advanced glycation end product interaction produces oxida‐
tive stress and subsequently evokes thrombosis and vascular inflammation, thereby playing
an important role in diabetic vascular complications (Yamagishi, 2009; Niiya et al., 2006). In
a recent study, median levels of malondialdehyde and increased plasma levels of soluble re‐
ceptor for advanced glycation end product were found in 42 type 1 diabetic patients during
the early years after diagnosis (0-10 years). These findings suggest that increased plasma
levels of soluble receptor for advanced glycation end product in type 1diabetes may provide
protection against cell damage and may be sufficient to eliminate excessive circulating ma‐
londialdehyde during early years after disease onset (Reis et al., 2012).
4. Free radicals formed during oxidative stress
4.1. Reactive oxygen species in type 1 diabetes
Reactive oxygen species consist of oxygen free radicals such as superoxide anion (O2•−), hy‐
drogen peroxide (H2O2), hydroxyl radical (•OH), singlet oxygen, nitric oxide, and peroxyni‐
trite (Chong et al., 2005). Most of these free radicals are produced at low concentrations
during normal physiological conditions in the body and are scavenged by endogenous en‐
zymatic and non-enzymatic antioxidant systems that include superoxide dismutase, gluta‐
thione peroxidase, catalase, and small molecule substances such as vitamins C and E.
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Reactive oxygen species induced tissue injury as well as they are involved in signaling path‐
ways and gene expression (Ha & Lee, 2000). Excess generation of reactive oxygen species
such as superoxide anion, hydrogen peroxide, hydroxyl radical and reactive nitrogen spe‐
cies such as nitric oxide oxidize target cellular proteins, nucleic acids, or membrane lipids
and damage their cellular structure and function (Brownlee, 2001). There is also evidence
that reactive oxygen species also regulate the expression of genes encoding for proteins in‐
volved in immune response, inflammation and cell death (Ho & Bray, 1999).
Hydroxyl radicals, hydrogen peroxide, and superoxide anion are byproducts of xanthine ox‐
idase. Xanthine oxidase and xanthine dehydrogenase catalyze the conversion of hypoxan‐
thine to xanthine and then to uric acid, with the former reducing oxygen as an electron
acceptor while the latter can reduce either oxygen or nicotinamide adenine dinucleotide
(NAD+) (Fatehi-Hassanabad et al., 2010). Superoxide anion is also produced by nicotinamide
adenine dinucleotide phosphate oxidases and cytochrome P450, and is the most commonly
occurring oxygen free radical that produces hydrogen peroxide by dismutation. This is ach‐
ieved via the Haber-Weiss reaction in the presence of ferrous iron by copper (Cu)-superox‐
ide dismutase or manganese (Mn)-superoxide dismutase. Mitochondrial superoxide anion is
produced from excess reduced nicotinamide adenine dinucleotide produced in the Krebs cy‐
cle (Fubini & Hubbard, 2003). Elevated free or non-esterified fatty acids in type 1 diabetic
patients enter the Krebs cycle causing the production of acetyl-CoA to subsequently excess
reduced nicotinamide adenine dinucleotide (Steinberg & Baron, 2002). The superoxide anion
undergo dismutation to hydrogen peroxide, which if not degraded by catalase or gluta‐
thione peroxidase, and in the presence of transition metals, can lead to production of hy‐
droxyl radical, the most active oxygen free radical. Hydroxyl radical alternatively may be
formed through an interaction between superoxide anion and nitric oxide (Fubini & Hub‐
bard, 2003; Wolff, 1993).
Superoxide anion can also react with nitric oxide to form the reactive peroxynitrite radicals
(Hogg & Kalyanaraman, 1998). Excess production of superoxide anion by the mitochondrial
electron transport chain, induced by hyperglycaemia has been reported to have a role in
triggering protein kinase C, hexosamine and polyol pathway fluxes, and advanced glycation
end product formation pathways which are involved in the pathogenesis of diabetic compli‐
cations (Nishikawa et al., 2000; Brownlee, 2001). In a study conducted by Hsu et al. (2006),
plasma superoxide anion (determined by a chemiluminescent assay) gave photoemission
which was considerably higher in 47 type 1 diabetic children than those in controls. The
findings confirm the presence of oxidative stress in children with type 1 diabetes mellitus
(Hsu et al., 2006).
4.2. Reactive nitrogen species in type 1 diabetes
Nitric oxide is an important regulator of endothelial function and the impairment of its ac‐
tivity is determinant of the endothelial dysfunction (Ignarro, 2002). It is an important vascu‐
lar target for ROS and is produced by constitutive and inducible nitric oxide synthases.
These enzymes oxidize L-arginine to citrulline in the presence of biopterin, reduced nicoti‐
namide adenine dinucleotide phosphate, and oxygen (Alp & Channon, 2004). Constitutive
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endothelial nitric oxide synthase contains reductase and oxygenase domains that are con‐
nected by a calmodulin-binding region and requires cofactor groups such as heme, flavin
mononucleotide, flavin adenine dinucleotide, tetrahydrobiopterin, and Ca2+-calmodulin for
activation (Gorren & Mayer, 2002; Andrew & Mayer, 1999). If there is none or insufficient L-
arginine, the endothelial nitric oxide synthase produce superoxide instead of nitric oxide
and this is referred to as the uncoupled state of nitric oxide synthase (Channon, 2004).
Oxidative stress decreases the bioavailability of endothelium-derived nitric oxide in diabetic
patients. In a 3-year longitudinal study involving 37 patients with recent-onset (less than 2
years) type 1 diabetes, oxidative stress was evident by elevated malondialdehyde excretion
and serum NOx (nitrate and nitrite) (Hoeldtke et al., 2011). In a latter study, NOx was also
higher in 99 female subjects with uncomplicated type 1 diabetes (duration disease <10 years)
compared with 44 sex-matched controls (Pitocco et al., 2009). Mylona Karayanni et al. (2006)
examined possible correlation between oxidative stress parameters and adhesion molecules
derived from endothelial/platelet activation, P-selectin and tetranectin in a group of juve‐
niles with type 1 diabetes mellitus. Significantly elevated NOx and lipid hydroperoxide lev‐
els, elevated tetranectin and P-selectin plasma levels, and lower glutathione peroxidase
activity were found in the diabetic children compared with healthy controls. Based on these
findings the authors suggested that decreased anti-oxidative protection from overproduc‐
tion of lipid hydroperoxide and NOx overproduction is present in juveniles with type 1 dia‐
betes mellitus. There is also a parallel endothelial/platelet activation which contributes to the
vascular complications of type 1 diabetes mellitus (Mylona-Karayanni et al., 2006).
Nitric oxide can react with superoxide to form peroxynitrite which in turn oxidizes tetrahy‐
drobiopterin and causes further uncoupling of nitric oxide formation (Yung et al., 2003). In
diabetes mellitus, elevated glucose may cause an increase in the expression of both reduced
nicotinamide adenine dinucleotide phosphate and of inducible nitric oxide synthase via the
activation of NF-κB, (Spitaler & Graier, 2002). The upregulated inducible nitric oxide syn‐
thase will synthesize the superoxide anion instead of nitric oxide, leading to oxidative and
nitrosative stress (Llorens & Nava, 2003). The stable protein adduct, nitrotyrosine, is a mark‐
er of peroxynitrite (Ischiropoulos, 1998) and nitrogen dioxide (Prutz et al., 1985). Moreover,
increased oxidative and nitrosative stress activates poly(ADP-ribose) polymerase-1, which
substrate, nicotinamide adenine dinucleotide (NAD+) as well as slows the rate of glycolysis,
electron transport, and adenosine triphosphate formation (Pacher & Szabó, 2006).
The formation of peroxynitrite can further lead to the generation of peroxynitrous acid. The
spontaneous decomposition of peroxynitrous acid results in the formation of hydroxyl radi‐
cals that can cause endothelial damage (Elliott et al., 1993; Beckman & Koppenol, 1996)
thereby reduces the efficacy the endothelium-derived vasodilator system that participates in
the general homeostasis of the vasculature (Benz et al., 2002). Overproduction of both nitric
oxide and superoxide anion has been reported in response to hyperglycemia (Cosentino et
al., 1997; Ceriello et al., 2002), and nitric oxide may work through peroxynitrite to directly
alter cellular structure and function (Pfeiffer et al., 2001). Increased nitric oxide levels have
been reported in both saliva and plasma of diabetic patients in comparison to healthy sub‐
jects (Astaneie et al., 2005).
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5. Enzymatics and non-enzymatic antioxidants
5.1. Intracellular enzymes activity in type 1 diabetes
A number of natural antioxidants are present in the body to scavenge oxygen free radicals
and prevent oxidative damage to biological membranes. Antioxidant defense mechanisms
involve both non-enzymatic and enzymatic strategies. One group of these antioxidants is in‐
tracellular enzymes such as manganese superoxide dismutase, catalase, glutathione peroxi‐
dase, and glutathione-S-transferases. These enzymes represent a protective mechanism
against the damage caused by the oxidative stress and most of these enzymes are polymor‐
phic (Fang et al., 2002; Mates et al., 1999).
Superoxide dismutase is considered a primary enzyme since it is involved in the direct elim‐
ination of reactive oxygen synthase (Halliwell, 1994). Isoforms of superoxide dismutase are
Cu/Zn-superoxide dismutase which is found in both the cytoplasm and the nucleus, and
Mn-superoxide dismutase that is present in the mitochondria. The latter can be released into
extracellular space (Reiter et al., 2000). Cu/Zn-superoxide dismutase over-expression inhib‐
its oxidized low density lipoprotein which is can elevate deoxyribonucleic acid binding ac‐
tivity of activator protein-1 and NF-κB (Yung et al., 2006). Superoxide dismutase catalyzes
the conversion of superoxide anion radicals produced in the body to hydrogen peroxide.
This decreases the possibility of superoxide anion interacting with nitric oxide to form reac‐
tive peroxynitrite (Reiter et al., 2000). Low Cu/Zn-superoxide dismutase is a potential early
marker of susceptibility to diabetic vascular disease. Suys et al. (2007) found that erythrocyte
superoxide dismutase activity and Cu/Zn-superoxide dismutase were higher in type 1 dia‐
betic subjects and was positively associated with flow-mediated dilatation. Based on these
findings the authors suggest that higher circulating Cu/Zn-superoxide dismutase could pro‐
tect type 1 diabetic children and adolescents against endothelial dysfunction (Suys et al.,
2007). Furthermore, Reznick and colleagues analyzed both serum and salivary superoxide
dismutase activity in 20 patients with type 1 diabetes mellitus. A significant association was
found between the level of glycemic control as indicated by the glycated hemoglobin values
and an increase in both salivary and serum superoxide dismutase activity (Reznick et al.,
2006). On the contrary, in a study which assessed correlations between increase of oxidative
stress and the development of microalbuminuria in 87 type 1 diabetic patients (44 with nor‐
mal urinary protein excretion, and 43 with microalbuminuria), there was a decreased in ac‐
tivity of superoxide dismutase. This was associated with an increased microalbuminuria in
type 1 diabetic patients (Artenie et al., 2005).
Selenium-dependent glutathione peroxidase works in conjunction with superoxide dismu‐
tase in protecting cell proteins and membranes against oxidative damage. In the literature,
glutathione peroxidase response to diabetes has been conflicting. Diabetics have been re‐
ported to be associated with increased glutathione peroxidase activity in 90 pregnant wom‐
en with type 1 diabetes mellitus (Djordjevic et al., 2004) and in young diabetic patients
(Ndahimana et al., 1996). On the other hand, decreased glutathione peroxidase activity was
reported in the early stages of type 1 diabetes in children and adolescents (Dominguez et al.,
1998) or unchanged in type 1 diabetic patients with early retina degenerative lesions (Faure
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et al., 1995). The low glutathione peroxidase activity could be directly explained by either
low glutathione content or enzyme inactivation under sever oxidative stress (Faure et al.,
1995). However, some authors found no differences between glutathione peroxidase activity
of type 1 diabetic patients and control subjects (Jain et al., 1994; Murakami et al., 1993;
Majchrzak et al., 2001).
Catalase, located in peroxisomes, decomposes hydrogen peroxide to water and oxygen (Win‐
terbourn & Metodiewa, 1994). In addition, glutathione peroxidase in the mitochondria and
the lysosomes also catalyses the conversion of hydrogen peroxide to water and oxygen (Yung
et al., 2006). A significant increase in the catalase activity in lymphocytes was found in 40 chil‐
dren with type 1 diabetes during all phases (at the beginning of diabetes, in remission period
and in the later chronic course) compared with the control group. The highest catalase activi‐
ty occurs in the early course of disease followed by a linear decrease and the lowest activity in
chronic course (Zivić, 2008). Conversely Dave and colleagues (2007) reported significant de‐
creased glutathione peroxidase, catalase and glutathione, and significant increase in thiobar‐
bituric acid reactive substances concentration in type 1 diabetic patients with and without
nephropathy compared with normal healthy individuals (Dave et al., 2007).
5.2. Non-enzymatic antioxidant levels in type 1 diabetes
In addition to enzymatic antioxidants, the major natural antioxidants, most of which are de‐
rived from dietary sources are vitamin A, vitamin C or ascorbic acid, vitamin E and carote‐
noids. Water-soluble vitamin C and fat-soluble vitamin E together make up the antioxidant
system for mammalian cells (Engler et al., 2003). Vitamins A, C, and E are obtained from the
diet and function to directly detoxify free radicals. Vitamin C forms the first line of defense
against plasma lipid peroxidation is considered the most important antioxidant in plasma
(Frei et al., 1990). Vitamin C under certain conditions may foster toxicity by generating pro-
oxidants, and is also engaged in the recycling processes which involved the generation of
reduced forms of the vitamins. In the processes of regeneration, α-tocopherol is reconstitut‐
ed when ascorbic acid recycles the tocopherol radical; dihydroascorbic acid, which is
formed, is recycled by glutathione (Weber, 1997).
Vitamin E involves all tocopherol and tocotrienol derivatives that comprise the major lipo‐
philic exogenous antioxidant in tissues (Di Mambro et al., 2003). Vitamin E, a component of
the total peroxyl radical-trapping antioxidant system reacts directly with superoxide and
peroxyl radicals, and singlet oxygen and in so doing protects membranes from lipid peroxi‐
dation (Weber & Bendich, 1997). In a study by Gupta et al. 2011 that evaluated the oxidative
stress in 20 type 1 diabetic children, reduced glutathione and vitamin E levels were de‐
creased and malondialdehyde levels were elevated compared with controls. After supple‐
mentation with vitamin E (600 mg/daily for three months) there was a significant decrease
in malondialdehyde levels and significant increase in glutathione and vitamin E. The find‐
ings indicate that vitamin E ameliorates oxidative stress in type 1 diabetes mellitus patients
and improves antioxidant defense system. In a latter study high-dose vitamin E supplemen‐
tation (1200 mg/day) reduces markers of oxidative stress and improves antioxidant defense
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in young patients with type 1 diabetes mellitus. However vitamin E supplementation did
not decreased albumin excretion rate in these patients (Giannini et al., 2007).
α-Tocopherol is very effective in lipid peroxidation inhibition and is the primary in vivo
chain-breaking, lipid-soluble antioxidant in human serum. A reduction in serum α-toco‐
pherol could be attributed to its consumption while scavenging free radicals in lipoproteins
or biomembranes (Frei, 1994). In the Pittsburgh Epidemiology of Diabetes Complications
Study cohort, a 10-year prospective study of childhood-onset type 1 diabetes, α-tocopherol
or γ-tocopherol did not showed protection against incident coronary artery disease overall.
However, high α-tocopherol levels among patients with renal disease and in those using vi‐
tamin supplements were associated with lower coronary artery disease risk in type 1 diabe‐
tes (Costacou et al., 2006). All the antioxidants work in a synergistic manner with each other
and against different types of free radicals. This is shown in the way in which vitamin E
suppresses the propagation of lipid peroxidation, and vitamin C working with vitamin E in‐
hibits hydroperoxide formation (Laight et al., 2000).
Glutathione functions as a direct free-radical scavenger, and as a co-substrate for glutathione
peroxidase activity (Meister & Anderson, 1983). Glutathione, a tri-peptide present in milli‐
molar concentrations is the most prevalent low-molecular weight peptide antioxidant in
cells. Reduced glutathione normally plays the role of a direct intracellular free-radical scav‐
enger through interaction with free radicals and is the substrate of many xenobiotic elimina‐
tion reactions (Gregus et al., 1996). It is also involved in other cellular functions such as the
elimination of hydrogen peroxide, detoxification processes such as protection of the sulf‐
hydryl group of cysteine in proteins, and regeneration of oxidized vitamin E (Lu, 1999). In
30 children with type 1 diabetes at onset, there was a significant reduction in all glutathione
forms (total, reduced, oxidized, and protein-bound glutathione). This indicates that there is
glutathione depletion upon early onset of type 1 diabetes mellitus (Pastore et al., 2012). In
another study, Likidlilid et al. (2007) compared the glutathione level, and glutathione perox‐
idase activity in 20 type 1 diabetic patients (with fasting glucose > 140 mg/dL) and a normal
healthy group. They found that the level of red cell reduced glutathione was significantly
lower in type 1 diabetic patients but red cell glutathione peroxidase activity was significant‐
ly increased. The decrease of red cell glutathione may be due to its higher rate of consump‐
tion, increasing glutathione peroxidase activity or a reduction of pentose phosphate
pathway, stimulated by insulin, resulting in lowered glutathione recycle (Likidlilid et al.,
2007). In a recent study, reduced glutathione and vitamin E levels were decreased and ma‐
londialdehyde levels were higher in 20 type 1 diabetic children compared with healthy con‐
trols. After supplementation with vitamin E (600 mg/daily for three months), there was a
significant decrease in malondialdehyde levels and significant increase in glutathione and
vitamin E levels. This shows that vitamin E ameliorates oxidative stress in type 1 diabetic
patients and improves antioxidant defense system (Gupta et al., 2011).
Other nonenzymatic antioxidants include α-lipoic acid, mixed carotenoids, coenzyme Q10,
several bioflavonoids, antioxidant minerals (copper, zinc, manganese and selenium), and
the cofactors (folic acid, vitamins B1, B2, B6, B12). β-carotene is a lipid soluble and chain-
breaking antioxidant that effectively quenches singlet oxygen and inhibits lipid peroxida‐
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tion. At low physiological oxygen pressures, it exhibits effective radical-trapping
antioxidant behaviour (Frei, 1994). Coenzyme Q10 has been found to have a very important
role in mitochondrial bioenergetics. It is an electron carrier-proton translocator in the respi‐
ratory chain and potent antioxidant which works by directly scavenging radicals or indirect‐
ly by regenerating vitamin E. In a study by Menke and colleagues (2008), plasma
concentrations of coenzyme Q10 in 39 children with type 1 diabetes mellitus were higher
than in healthy children. The findings suggest that elevated plasma concentration and the
intracellular redox capacity of coenzyme Q10 in diabetic children may contribute to the
body’s self-protection during a state of enhanced oxidative stress (Menke et al., 2008). In an‐
other study, Salardi and colleagues (2004) determine whether serum hydroperoxides as oxi‐
dative markers and vitamin E and coenzyme Q10 as indexes of antioxidant capacity could be
related to metabolic control in 75 unselected children, adolescents, and young adults with
type 1 diabetes. Vitamin E and coenzyme Q10 were not significantly different from age-
matched control subjects. However, there were significant positive correlations between
coenzyme Q10 and glycated hemoglobin, and vitamin E and glycated hemoglobin. It was al‐
so observed that diabetic patients with poor metabolic control and complications had elevat‐
ed vitamin E levels and coenzyme Q10 levels (Salardi et al., 2004).
Small molecules that have antioxidant capacity such as glutathione and uric acid are synthe‐
sized or produced within the body (Engler et al., 2003). A study by Maxwell et al. (1997)
found significantly reduced total serum antioxidant status in 28 patients with type 1 diabe‐
tes mellitus as attributed by lower uric acid and vitamin C levels. Furthermore, multiple re‐
gression analysis showed that uric acid, vitamin E and vitamin C were the main
contributors to serum total antioxidant activity.
6. Markers of oxidative stress in type 1 diabetes
6.1. Biomarkers of lipid peroxidation in type 1 diabetes
Oxidative stress and its contribution to low-density lipoprotein oxidation have been impli‐
cated in the pathogenesis of vascular diabetic complications. Diabetes produces disturban‐
ces of lipid profiles, especially an increased susceptibility to lipid peroxidation, which is
responsible for increased incidence of atherosclerosis, a major complication of diabetes mel‐
litus (Siu & To, 2002). Polyunsaturated fatty acids with multiple bonds and lipoproteins in
the plasma membrane are very susceptible to attack by reactive oxygen species (Esterbauer
& Schaur, 1991). The hydroxyl radicals extract a hydrogen atom from one of the carbon
atoms in the polyunsaturated fatty acid and lipoproteins, initiating a free radical chain reac‐
tion which leads to lipid peroxidation. This characterized by membrane protein damage
through subsequent free radical attacks (Halliwell, 1995). Lipid peroxidation can produce
advanced products of oxidation, such as aldehydes, alkanes and isoprostanes (Moore &
Roberts, 1998). Elevation of lipid peroxidation negatively affects membrane function causing
reduced membrane fluidity and changing the activity of membrane bound enzymes and re‐
ceptors (Acworth et al., 1997).
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In diabetes mellitus, persistence of hyperglycemia was reported to cause increased produc‐
tion of oxidative parameters of lipid peroxidation including malondialdehyde. In a study by
Firoozrai and colleagues (2007), malondialdehyde levels were significantly elevated in diabet‐
ic patients. The level of malondialdehyde was positively correlated with duration of diabetes
and glycated hemoglobin and negatively with ferric reducing ability of plasma (Firoozrai et
al., 2007). In a latter study that investigated the effect of glycemic control on oxidative stress
and the lipid profile of pediatric type 1 diabetes mellitus patients, total cholesterol, low densi‐
ty lipoprotein-cholesterol, apolipoprotein A, apolipoprotein B, and malondialdehyde levels
were significantly elevated compared with controls. In addition, serum malondialdehyde lev‐
els and malondialdehyde/low density lipoprotein-cholesterol index were significantly elevat‐
ed in metabolically poorly controlled in relation to metabolically well-controlled diabetic
patients. Based on these findings the authors suggested that type 1 diabetic children, especial‐
ly those who are metabolically poorly controlled are at high risk of atherosclerosis and vascu‐
lar complications of diabetes mellitus, and that there is a significant relationship between the
lipid profile and oxidative stress (Erciyas et al., 2004).
Isoprostanes are prostaglandin-like compounds formed through peroxidation of arachidonic
acid, and have been used extensively as biomarkers of lipid peroxidation as a risk factor for
atherosclerosis and other diseases (Roberts & Marrow, 2000). Oxidative stress parameters
such as advanced oxidation protein products, total peroxyl radical-trapping antioxidant pa‐
rameter, and F2-isoprostanes (8-epi-prostaglandin-F2: 8-isoPGF2alpha) were not significant‐
ly different in 27 pre-pubertal patients with type 1 diabetes mellitus (with less than 5 years
of disease) compared with controls (Gleisner et al., 2006). In another study, Flores and col‐
leagues (2004) evaluated the effect of the normalization of blood glucose levels on urinary
F2-isoprostanes at the onset of type 1 diabetes in 14 patients. There was a statistically signifi‐
cant reduction in F2-isoprostanes after insulin therapy (after 16 weeks) which was accompa‐
nied by a significant reduction in glycated hemoglobin (Flores et al., 2004).
Lipid hydroperoxides are potentially atherogenic and are degraded by enzymes such as para‐
oxonase-1 and lipoprotein-associated phospholipase A2 (Van Lenten et al., 2001; Macphee et
al., 2005). Paraoxonase-1 is an enzyme associated with high density lipoprotein surface and
the antioxidant effect of the latter is partially related to paraoxonase. This enzyme is able to
hydrolyze lipid hydroperoxides and to delay or inhibit the initiation of oxidation of lipopro‐
teins induced by metal ions (Watson et al., 1995). It has been suggested that individuals with
low paraoxonase-1 activity may have a greater risk of developing diseases such as diabetes
mellitus in which oxidative damage and lipid peroxidation are involved, compared with
those with high paraoxonase-1 activity (Durrington et al., 2001; Nourooz-Zadehet al., 1995).
Wegner et al. (2011) reported that 80 type 1 diabetic patients had lower paraoxonase-1 ary‐
lesterase activity and higher lipid hydroperoxide levels, and that there was a negative corre‐
lation between paraoxonase-1arylesterase activity and lipid hydroperoxide levels. In a latter
study, paraoxonase-1 activity was reduced in patients with type 1 diabetes mellitus with ret‐
inopathy, confirming that oxidative stress could play a role in pathogenesis of diabetic retin‐
opathy (Nowak et al., 2010). A similar finding of lower high density lipoprotein-
paraoxonase-1 activity in 31 type 1 diabetic patients compared with the same number of sex-
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and age-matched healthy subjects was reported by Ferretti et al. (2004). These findings
confirm a linkage between paraoxonase-1 activity and lipid peroxidation of lipoproteins and
suggest that the ability of high density lipoprotein to protect erythrocyte membranes might
be related to the paraoxonase-1 activity (Ferretti et al., 2004). The low paraoxonase-1 aryles‐
terase activity suggests insufficient high density lipoprotein capacity to protect against lipid
oxidation in patients with type 1 diabetes (Wegner et al., 2011). It is also hypothesized that
the lower high density lipoprotein protective action against membrane peroxidation and de‐
crease paraoxonase-1 activity in diabetic patients could contribute to acceleration of arterio‐
sclerosis in patients with type 1 diabetes mellitus (Ferretti et al., 2004). Furthermore, there
are several studies linking diabetes and even postprandial hyperglycemia with increased
low density lipoprotein oxidative susceptibility (Ceriello, 2000). Decreased insulin in diabe‐
tes mellitus increases the activity of fatty acyl coenzyme A oxidase, which intiates β-oxida‐
tion of fatty acids, resulting in lipid peroxidation (Horie et al., 2006).
6.2. Biomarkers of protein peroxidation and oxidative damage to DNA in type 1 diabetes
High plasma glucose concentrations can increase the levels of glycation and oxidative dam‐
age to cellular and plasma proteins in diabetes mellitus. Glycation of proteins is a complex
series of reactions where early-stage reactions leads to the formation of the early glycation
adduct, fructosyl-lysine and NH2-terminal fructosyl-amino acids, and later-stage reactions
form advanced glycation end products (Thornalley, 2002). The oxidation of proteins produ‐
ces nitrotyrosine and protein carbonyl derivatives and nitrotyrosine (Adams et al., 2001).
The oxidized or nitrosylated products of free radical attack have reduced biological activity,
leading to loss of cell signaling, energy metabolism, transport, and other major cellular func‐
tions. These altered oxidized products also are targeted for proteosome degradation, further
reducing cellular function. There is also cell death through necrotic or apoptotic mecha‐
nisms as a result of the accumulation of cellular injury (Rosen et al., 2001).
Carbonyl group formation is considered an early and stable marker for protein oxidation in
the body. Diabetes mellitus is associated with carbonyl stress where there is an increase of
reactive carbonyl compounds caused by their enhanced formation and/or decreased degra‐
dation or excretion (Miyata et al., 1999.) This leads to the formation of advanced glycation
end products such as pentosidin and carboxymethyllysine and advanced oxidation protein
products, and damage to a number of biologically important compounds (Miayta et al. 1999;
Witko-Sarsat et al., 1996). Telci et al. (2000) examined the influence of oxidative stress on oxi‐
dative protein damage in 51 young type 1 diabetic patients clinically free of complications
and 48 healthy normolipidaemic age-matched controls. The levels of plasma carbonyl and
plasma lipid hydroperoxide were increased in adolescent and young adult type 1 diabetic
patients compared with controls.
Modifications in endothelial cell function are proposed to play an important role in athero‐
genesis. These perturbations include increased permeability to circulating lipoproteins par‐
ticularly low density lipoprotein, increased retention of these lipoproteins, the loss of
endothelial cell-directed vasodilatation, and the increased expression of intercellular cell ad‐
hesion molecule-1 and vascular cell adhesion molecule-1 (Ross, 1999). Koitka et al. (2004) re‐
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ported evidence of endothelial dysfunction in patients with type 1 diabetes. In another
study of 45 type 1 diabetic children, there was significantly lower peak brachial artery flow-
mediated dilation response and increased carotid artery intima-media thickness. This sug‐
gests that altered endothelium function in children with type 1 diabetes may predispose
them to the development of early atherosclerosis (Jarvisalo et al., 2004). Furthermore, in a
double-blind, placebo-controlled, randomized study of 41 young subjects with type I diabe‐
tes mellitus, vitamin E supplementation (1,000 IU for three months) had a positive effect on
the endothelial function as evident by improved endothelial vasodilator function in both the
conduit and resistance vessels (Skyrme-Jones, 2000).
In addition to lipids and proteins, reactive oxygen species reacts with deoxyribonucleic acid
resulting in various products, such as 8-hydroxydeoxyguanosine, that is excrete in urine ow‐
ing to deoxyribonucleic acid repair processes. Urinary 8-hydroxydeoxyguanosine has been
proposed as an indicator of oxidative damage to deoxyribonucleic acid. Goodarzi and col‐
leagues (2010) evaluated the relationship between oxidative damage to deoxyribonucleic
acid and protein glycation in 32 patients with type 1 diabetes. There were elevated levels of
urinary 8-hydroxydeoxyguanosine, glycated hemoglobin, plasma malondialdehyde, and
glycated serum protein in 32 patients with type 1 diabetes. There was a significant correla‐
tion between urinary 8-hydroxydeoxyguanosine and glycated hemoglobin. The findings in‐
dicate that that deoxyribonucleic acid is associated to glycemic control level (Goodarzi et al.,
2010). In a study which investigated whether advanced glycation end product production
and oxidative stress are augmented in young patients with type 1 diabetes at early clinical
stages of the disease, advanced glycation end products, pentosidine, and 8-hydroxydeoxy‐
guanosine and acrolein-lysine were significantly higher in the patients with type 1 diabetes
compared with healthy control subjects (Tsukahara et al., 2003).
6.3. Biomarkers of oxidative stress present in breath
Oxidative stress has been implicated in the major complications of diabetes mellitus, includ‐
ing retinopathy, nephropathy, neuropathy and accelerated coronary artery disease (Ceriello
& Morocutti, 2000; Androne et al., 2000; Mackness et al., 2002). There is a clinical need for
markers of oxidative stress which could potentially identify diabetic patients at increased
risk for these complications. The introduction of breath microassays has enhanced the detec‐
tion of oxidative stress because reactive oxygen species oxidize polyunsaturated fatty acids
in membranes to alkanes such as ethane and pentane. These are excreted in the breath as
volatile organic compounds (Kneepkens & Lepage, 1994). Another marker of oxidative
stress is the breath methylated alkane contour, comprising a three-dimensional display of
C4 to C20 alkanes and monomethylated alkanes in the breath (Phillips et al., 2004). Phillips
et al. (2004) reported significantly increased volatile organic compounds and breath methy‐
lated alkane contour in the breath of type 1 diabetic patients which was independent of gly‐
cemic as they did with blood glucose concentration or with glycation hemoglobin levels.
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7. Conclusion
This review presented convincing experimental and clinical evidence that the aetiology of
oxidative stress in diabetes mellitus arises from a number of mechanisms that includes ex‐
cessive reactive oxygen species production from the peroxidation of lipids, auto-oxidation of
glucose, glycation of proteins, and glycation of antioxidative enzymes, which limit their ca‐
pacity to detoxify oxygen radicals. There is also evidence that supports the role of hypergly‐
cemia in producing oxidative stress and, eventually, severe endothelial dysfunction in blood
vessels of individuals with type 1 diabetes mellitus. The induction of oxidative stress is a
key process in the onset and development of diabetic complications, but the precise mecha‐
nisms has not been fully elucidated. A number of biomarkers of oxidative stress have been
studied in type 1 diabetic patients such as malondialdehyde, F2-isoprostanes, advanced gly‐
cation end product and nitrotyrosine. The introduction of breath microassays has enhanced
the detection of oxidative stress.
Type 1 diabetic patients have been found to have decreased amounts and efficiency of anti‐
oxidant defenses (both enzymatic and non-enzymatic) due to increased consumption of dis‐
tinct antioxidant components (e.g. intracellular glutathione) or to primarily low levels of
antioxidant substances (flavonoids, carotenoids, vitamin E and C). This review also presents
small clinical studies that have demonstrated improvements in a variety of oxidative stress
biomarkers in type 1 diabetic patients who have received vitamin A, C or E supplements.
However, the findings of key prospective randomized controlled antioxidant clinical trials
have failed to demonstrate a significant benefit, in the prevention of cardiovascular events.
There is a need for continued investigation of the association between reactive oxygen spe‐
cies, type 1 diabetes mellitus and its complications in order to clarify the molecular mecha‐
nisms by which increased oxidative stress accelerates the development of diabetic
complications. This will have implication for the prevention and development of therapeutic
choices for type 1 diabetic patients.
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